Royalty Report: Medical, Supply, Device – Collection: 5337


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Medical
  • Supply
  • Device
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5337

License Grant
The Licensors hereby grant to the Licensee, and the Licensee hereby accepts, an exclusive license worldwide to make use and sell Product (hereinafter referred to as the 'License').  Such license is perpetual, subject to the payment of royalties and other obligations of the Licensee herein.
License Property
The Licensors have developed a material used in and around implantable prosthetic devices (called Bio-Oncotic Gel (United States Patent No. 5,067,965)), and have invented certain breast implant products, along with methods and materials to manufacture the breast implants.

U.S. Patent 4,955,909 September 11, 1190 (S.N. 07/496,234)
U.S. Patent 5,260,965 November 26, 1191 (S.N. 07/304,764)
U.S. Patent 5,997,574 and any corresponding foreign patent applications U.S. Patent 5,630,844 and any corresponding foreign patent applications U.S. Patent 6,162,251 and any corresponding foreign patent applications U.S. Patent 09/452,656 and any corresponding foreign patent applications.

IPSCIO Record ID: 1686

License Grant
Inventors, two of whom are former officers and directors of the Licensee hereby grant and Licensees hereby accept exclusive licenses for the entire world to make, use and sell Products. Such licenses are perpetual, subject to the payment of royalties as provided herein.
License Property
'Gel Patents' shall refer to United States Patent No. 5,067,965, Bio-Oncotic Gel for Implant Protheses
'Micro Implant Patents and Patent Applications' refers to United States patent Application Serial Number 07/232,671, an Application, allowed in part and issued on November 2, l993, as Patent No. 5,258,028, United States Patent for Textured Micro Implants

'Reflux Disorders Patent Application' refers to United States Patent Application Serial Number 07/863,848, entitled Treatment of Urologic and Gastric Fluid Reflux Disorders by Injection of Micro Particles

Field of Use
Multiple patents Macroplastique(r) Implants are an injectable medical device implant designed to treat certain forms of urinary / in a minimally invasive procedure involving injection of the product material through a needle into the soft tissue at the bladder neck to act as a tissue bulking agent.

IPSCIO Record ID: 5941

License Grant
Licensee acquired the exclusive rights to the CardioSEAL® cardiac septal repair implant from the Licensor, a non-profit health care organization.   In connection with this acquisition, the Licensee acquired all of the existing development, manufacturing, testing equipment, patent Licenses, know-how and documentation necessary to manufacture cardiac septal repair implant devices. Under the License Agreements, as amended, the Licensee pays royalties to the Licensor on all commercial sales of our cardiac septal repair products. The Territory for sales of CardioSEAL® is the United States, Canada and Europe. The Licensee sells STARFlex® in Europe.
License Property
CardioSEAL® and STARFlex® are revolutionary products designed to close different types of holes in the heart without open heart surgery.  CardioSEAL®, a third generation implant, is constructed from a low profile, metal framework shaped like an umbrella to which a knitted polyester fabric is securely attached. CardioSEAL is comprised of two of these umbrellas, one for each side of the septum. Both the metal and fabric are made from the most biocompatible materials known for this application. The framework in particular has been selected for its excellent biocompatibility profile. After all, this implant will be in place for the life of the patient.

The Licensee has an exclusive worldwide License from the Licensor under United States patents entitled Occluder and Method for Repair of Cardiac and Vascular Defects (U.S. Patent No. 5,425,744), Occluder for Repair of Cardiac and Vascular Defects (U.S. Patent No. 5,451,235) and Self-Centering Umbrella-Type Septal Closure Device (U.S. Patent No. 5,709,707) and the respective corresponding foreign patents, patent applications and associated know-how.

Field of Use
The rights granted apply to cardiac products.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.